NLRP3 and type 2 diabetes mellitus: This systematic review has highlighted a significant increase in biomarkers of the activated NLRP3 inflammasome, IL-1β and IL-18, in the vitreous as DR develops in T2DM patients, suggesting activation of the inflammasome plays a major role in initiating inflammation in DR.